|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0038952,
umls-concept:C0205489,
umls-concept:C0237865,
umls-concept:C0278883,
umls-concept:C0282460,
umls-concept:C0679729,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1518578,
umls-concept:C1533691,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1881197,
umls-concept:C2911692
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2006-9-26
|
|
pubmed:abstractText |
In vitro sensitivity assays are promising tools to predict the individual outcome of different chemotherapy regimens. However, a direct association between in vitro and in vivo chemosensitivity has to be shown by clinical studies. This multicenter phase II trial was aimed to investigate the efficacy of a sensitivity-directed, first-line chemotherapy in metastasized melanoma patients, and to prove an association between in vitro sensitivity and therapy outcome.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:DelormeStefanS,
pubmed-author:Dermatologic Cooperative Oncology Group,
pubmed-author:HauschildAxelA,
pubmed-author:KaatzMartinM,
pubmed-author:NeuberKarstenK,
pubmed-author:PföhlerClaudiaC,
pubmed-author:ReinholdUweU,
pubmed-author:RittgenWernerW,
pubmed-author:SchadendorfDirkD,
pubmed-author:SpiethKonstanzeK,
pubmed-author:ThoelkeAdinaA,
pubmed-author:TilgenWolfgangW,
pubmed-author:UgurelSelmaS,
pubmed-author:UlrichJensJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5454-63
|
|
pubmed:meshHeading |
pubmed-meshheading:17000680-Adult,
pubmed-meshheading:17000680-Aged,
pubmed-meshheading:17000680-Aged, 80 and over,
pubmed-meshheading:17000680-Algorithms,
pubmed-meshheading:17000680-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17000680-Busulfan,
pubmed-meshheading:17000680-Cisplatin,
pubmed-meshheading:17000680-Deoxycytidine,
pubmed-meshheading:17000680-Doxorubicin,
pubmed-meshheading:17000680-Drug Resistance, Neoplasm,
pubmed-meshheading:17000680-Drug Screening Assays, Antitumor,
pubmed-meshheading:17000680-Female,
pubmed-meshheading:17000680-Humans,
pubmed-meshheading:17000680-Male,
pubmed-meshheading:17000680-Melanoma,
pubmed-meshheading:17000680-Middle Aged,
pubmed-meshheading:17000680-Paclitaxel,
pubmed-meshheading:17000680-Skin Neoplasms,
pubmed-meshheading:17000680-Survival Analysis,
pubmed-meshheading:17000680-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
|
|
pubmed:affiliation |
Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany. s.ugurel@dkfz.de
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
